Skip to main content
Premium Trial:

Request an Annual Quote

RZPD Expands NimbleGen Array Services Offering to Include Affy IP

 

NEW YORK (GenomeWeb News) - The German Resource Center for Genome Research (RZPD), based in Berlin, said it has expanded an agreement with NimbleGen to cover Affymetrix’ microarray patents in Germany and Austria.
 
NimbleGen signed an agreement with Affymetrix in October that gave it non-exclusive, worldwide rights for the manufacture, use, and sale of nucleic acid microarrays.
 
Under the new agreement, RZPD will be able to offer technology covered by this IP to its customers as part of its services offering.
 
RZPD has been a distributor for NimbleGen in Germany and Austria for three years. It offers services such as ChIP-chp, comparative genomic hybridization, and gene expression analysis based on the NimbleGen platform.
The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.